Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis

Clinical Transplantation

Volumn 27, Issue 2, 2013, Pages

  Du, Kaili ^a   Hu, Yongxian ^a   Wu, Kangni ^a   Huang, He ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Antithymocyte globulin; Chronic graft versus host disease; T cell depletion

Indexed keywords

THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; HEMATOLOGIC MALIGNANCY; HUMAN; META ANALYSIS; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ANTILYMPHOCYTE SERUM; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, STATISTICAL; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84876085522     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12091     Document Type: Review

References (43)

1. Martin PJ, Counts GJ, Appelbaum FR et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010: 28: 1011.
2. Wingard JR, Majhail NS, Brazauskas R et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011: 29: 2230.
3. Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 2011: 1: e16.
4. Antin JH, Kim HT, Cutler C et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003: 102: 1601.
5. Cutler C, Li S, Ho VT et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007: 109: 3108.
6. Bacigalupo A, Lamparelli T, Bruzzi P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001: 98: 2942.
7. Finke J, Bethge WA, Schmoor C et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009: 10: 855.
8. Kumar A, Mhaskar AR, Reljic T et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia 2012: 26: 582.
9. Theurich S, Fischmann H, Shimabukuro-Vornhagen A et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev 2012: 9: D9159.
10. Mohty M, Labopin M, Balere ML et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 2010: 24: 1867.
11. Bacigalupo A, Lamparelli T, Barisione G et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006: 12: 560.
12. Bacigalupo A, Lamparelli T, Gualandi F et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 2002: 8: 656.
13. Appelbaum FR, Bacigalupo A, Soiffer R. Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation-a debate. Biol Blood Marrow Transplant 2012: 18(1 Suppl): S111.
14. Socie G, Schmoor C, Bethge WA et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011: 117: 6375.
15. Zander AR, Kroger N, Schleuning M et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003: 32: 355.
16. Yu ZP, Ding JH, Wu F et al. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin. Biol Blood Marrow Transplant 2012: 18: 593.
17. Russell JA, Turner AR, Larratt L et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007: 13: 299.
18. Kroger N, Zabelina T, Kruger W et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002: 29: 683.
19. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999: 354: 1896.
20. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000: 283: 2008.
21. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980: 69: 204.
22. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998: 52: 377.
23. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007: 8: 16.
24. Remberger M, Storer B, Ringden O, Anasetti C. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002: 29: 391.
25. Basara N, Baurmann H, Kolbe K et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005: 35: 1011.
26. Veys P, Wynn RF, Ahn KW et al. Impact of immune modulation with in vivo T-cell depletion and myeloablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood 2012: 119: 6155.
27. Linhares YP, Pavletic S, Gale RP. Chronic GVHD: where are we? Where do we want to be? Will IMiDs help?. Bone Marrow Transplant 2012 May 14. doi: 10.1038/bmt.2012.76. [Epub ahead of print].
28. Bonifazi F, Bandini G, Stanzani M et al. In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. Bone Marrow Transplant 2005: 35: 1025.
29. Kakhniashvili I, Filicko J, Kraft WK, Flomenberg N. Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2005: 11: 609.
30. Gurkan S, Luan Y, Dhillon N et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010: 10: 2132.
31. Klaus G, Mostert K, Reckzeh B, Mueller TF. Phenotypic changes in lymphocyte subpopulations in pediatric renal-transplant patients after T-cell depletion. Transplantation 2003: 76: 1719.
32. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006: 17: 2844.
33. Shimony O, Nagler A, Gellman YN et al. Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. J Clin Immunol 2012: 32: 173.
34. LaCorcia G, Swistak M, Lawendowski C et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009: 87: 966.
35. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006: 82: 1387.
36. Kohrt HE, Turnbull BB, Heydari K et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009: 114: 1099.
37. Ayuk F, Diyachenko G, Zabelina T et al. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol 2008: 36: 1047.
38. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 2003: 21: 506.
39. Duggan P, Booth K, Chaudhry A et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002: 30: 681.
40. Portier DA, Sabo RT, Roberts CH et al. Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients. Bone Marrow Transplant 2012: 47: 1513.
41. Feng X, Kajigaya S, Solomou EE et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25 high FOXP3+ regulatory T cells in vitro. Blood 2008: 111: 3675.
42. Hamadani M, Blum W, Phillips G et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009: 15: 1422.
43. Ayuk F, Diyachenko G, Zabelina T et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008: 14: 913.